Bayer AG Sponsored ADR (BAYRY)
Bayer must pay $100 million in latest trial over PCBs in Washington school, jury finds
A Washington state jury on Tuesday said Bayer must pay $100 million to four people who say they were sickened by exposure to toxic chemicals known as PCBs made by the company's predecessor Monsanto that were used in light fixtures at a Seattle-area school, but found that the company was not liable for injuries alleged by ten others, according to a lawyer for the plaintiffs.
Bayer pharma chief sees no big acquisitions in near future
Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the German company's pharmaceuticals division said in an interview published on Tuesday.
Bayer's Stock Hits 2-Decade Low: Why It Is A Buy Again
Bayer's stock has declined below €20, with Q3/24 results showing a 3.6% sales decrease and a 29.8% EBITDA drop, mainly due to currency effects. Crop Science sales fell 9.1% YoY, and Pharmaceuticals saw mixed results with Nubeqa and Kerendia growing, but Xarelto declining 23.8% due to generics. Bayer's strategic transformation under CEO Bill Anderson aims to decentralize decision-making, but litigation issues and high debt levels remain significant challenges.
FDA Accepts Bayer's Application for Label Expansion of Nubeqa
Bayer's efforts to expand Nubeqa's label in prostate cancer make progress with the FDA's acceptance of the company's sNDA.
Bayer shareholders call on CEO to stem the tide of bad news
Some Bayer investors say CEO Bill Anderson should speed up turnaround efforts, including boosting efficiency and drug development, to restore confidence and revive the company's share price that hit 20-year lows after its shock warning this week.
Bayer Q3 Earnings Miss Estimates, Nubeqa, Kerendia Boost Sales
BAYRY's third-quarter earnings get affected due to impairment losses at the Crop Science division. Sales gain from the Pharmaceutical business's strong performance.
Bayer Stock: Assessing Upside Potential After Its Q3 Earnings
Bayer faces significant risks from litigation and poor M&As, but its current low valuation presents a potential long-term upside, especially post-2025. Despite recent challenges and a dividend cut, Bayer's fundamentals remain solid, with potential for a 30% annual upside in the long term. Key segments like Consumer Health show promise, but Crop Science and Pharma face headwinds, including generic competition and muted market growth.
Bayer Stock Slumps on Outlook Cut
Bayer shares are falling 11% in German trading after the pharmaceuticals and crop science conglomerate reduced its full-year earnings target and warned of likely lower profit next year amid a tough agricultural market.
Bayer's stock slumps after warning on crop-sciences unit
Bayer's stock slumped on Tuesday as the German giant gave a profit warning on agricultural demand.
Bayer cuts FY operating earnings outlook on weak agriculture markets
Bayer on Tuesday lowered its full-year operating earnings guidance, citing weaker agricultural markets in Latin America.
Bayer Seeks Approval for Elinzanetant for Vasomotor Symptoms in EU
BAYRY submits an application seeking EMA approval of elinzanetant for treating hot flashes associated with menopause or adjuvant endocrine therapy.
Bayer submits EU marketing application for menopause relief drug
Bayer on Tuesday said it had applied for marketing authorization with the European Medicines Agency (EMA) for its menopause relief drug elinzanetant.
